Influenza A virus subtype H5N6

From WikiMD's WELLNESSPEDIA

Influenza A virus subtype H5N6 is a subtype of the Influenza A virus that has been identified as a potential future pandemic threat. It is a subtype of the species Influenza A virus of the Orthomyxoviridae family of viruses.

Overview[edit]

The Influenza A virus subtype H5N6 is a subtype of viruses that causes influenza in birds and some mammals. It is a combination of several other avian influenza viruses. The subtype was first detected in 2014 and has since been identified in several countries, including China, Vietnam, and the Netherlands.

Structure and Composition[edit]

Like all Influenza A viruses, H5N6 is an Orthomyxovirus, with a genome composed of eight single-stranded negative-sense RNA segments. The H5N6 subtype is characterized by the hemagglutinin 5 (H5) and neuraminidase 6 (N6) proteins on its surface.

Pathogenesis[edit]

The H5N6 subtype is highly pathogenic in birds, causing severe disease and high mortality rates. In humans, the virus can cause severe respiratory illness, with symptoms including fever, cough, and shortness of breath. The virus is transmitted from birds to humans through direct contact with infected birds or their droppings, or indirectly through contaminated environments.

Prevention and Control[edit]

Prevention and control of H5N6 outbreaks in poultry are critical to reducing the risk of human infection. Measures include surveillance for early detection of outbreaks, culling of infected and exposed birds, and vaccination of poultry. In humans, antiviral drugs can be used for treatment and prophylaxis.

See Also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.